|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 CAD | +50.00% |
|
+50.00% | -25.00% |
| 05-22 | Waverley Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 04-30 | Waverley Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Waverley Pharma Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 6.75 | 4.32 | 1.62 | 1.35 | 0.54 | 1.08 |
| Change | - | -36% | -62.5% | -16.67% | -60% | 100% |
| Enterprise Value (EV) 1 | 6.08 | 4.424 | 2.188 | 2.899 | 3.37 | 4.479 |
| Change | - | -27.23% | -50.55% | 32.5% | 16.26% | 32.9% |
| P/E Ratio | -9.56x | -5.42x | -2.44x | -0.61x | -0.57x | -2.16x |
| PBR | 3.3x | 2.41x | 1.48x | -1.19x | -0.27x | -0.42x |
| PEG | - | -0.4x | 0.1x | -0x | 0x | 0x |
| Capitalization / Revenue | 4.91x | 2.46x | 1.3x | 3.28x | 1.14x | 0.8x |
| EV / Revenue | 4.42x | 2.52x | 1.75x | 7.03x | 7.09x | 3.32x |
| EV / EBITDA | -8.67x | -5.83x | -2.64x | -3.02x | -3.99x | -15.4x |
| EV / EBIT | -8.57x | -5.62x | -2.34x | -2.26x | -3.91x | -12.8x |
| EV / FCF | -12.1x | -7.92x | -5.01x | -3.62x | -15.2x | -8.87x |
| FCF Yield | -8.23% | -12.6% | -20% | -27.6% | -6.6% | -11.3% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.0131 | -0.0148 | -0.0123 | -0.0412 | -0.0175 | -0.009244 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 1.375 | 1.753 | 1.247 | 0.4121 | 0.4754 | 1.35 |
| EBITDA 1 | -0.7014 | -0.7587 | -0.8284 | -0.9609 | -0.8451 | -0.2915 |
| EBIT 1 | -0.7096 | -0.7868 | -0.9361 | -1.283 | -0.862 | -0.3493 |
| Net income 1 | -0.7058 | -0.7965 | -0.6641 | -2.224 | -0.9471 | -0.4992 |
| Net Debt 1 | -0.6705 | 0.1042 | 0.5679 | 1.549 | 2.83 | 3.399 |
| Reference price 2 | 0.1250 | 0.0800 | 0.0300 | 0.0250 | 0.0100 | 0.0200 |
| Nbr of stocks (in thousands) | 54,000 | 54,000 | 54,000 | 54,000 | 54,000 | 54,000 |
| Announcement Date | 4/26/21 | 4/29/22 | 4/27/23 | 4/29/24 | 4/29/25 | 4/30/26 |
1CAD in Million2CAD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 580K | |
| 33.17x | 8.64x | 26.13x | 0.05% | 56.42B | |
| 16.69x | 5.03x | 10.91x | 1.8% | 44.54B | |
| -17.8x | 4.17x | -7.3x | -.--% | 22.9B | |
| -36.36x | 12.23x | -35.67x | -.--% | 21.21B | |
| 20.25x | 3.95x | 10.26x | -.--% | 16.4B | |
| 21.44x | 4.3x | 14.23x | -.--% | 15.4B | |
| 16.8x | 4.85x | 11.36x | -.--% | 13.35B | |
| -433.48x | 29.5x | -3289.39x | -.--% | 12.36B | |
| 36.9x | 14.16x | 41.61x | 0.18% | 11.15B | |
| Average | -38.04x | 9.65x | -357.54x | 0.23% | 21.37B | |
| Weighted average by Cap. | -12.27x | 8.35x | -180.62x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- WAVE Stock
- Valuation Waverley Pharma Inc.
Select your edition
All financial news and data tailored to specific country editions
